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Abstract Synbiotics are known to exert multiple beneficial
effects, including anti-inflammatory and antioxidative actions.
This study was designed to evaluate the effects of synbiotic
administration on biomarkers of inflammation, oxidative
stress, and pregnancy outcomes among gestational diabetic
(GDM) women. This randomized, double-blind, placebo-
controlled clinical trial was carried out among 60 subjects with
GDM who were not on oral hypoglycemic agents. Patients
were randomly assigned to consume either one synbiotic cap-
sule containing Lactobacillus acidophilus strain T16 (IBRC-
M10785), L. casei strain T2 (IBRC-M10783), and
Bifidobacterium bifidum strain T1 (IBRC-M10771)
(2 × 109 CFU/g each) plus 800 mg inulin (HPX) (n = 30) or
placebo (n = 30) for 6 weeks. Compared with the placebo,
synbiotic supplementation significantly decreased serum
high-sensitivity C-reactive protein (hs-CRP) (− 1.9 ± 4.2 vs.
+1.1 ± 3.5 mg/L, P = 0.004), plasmamalondialdehyde (MDA)
(− 0.1 ± 0.6 vs. + 0.3 ± 0.7 μmol/L, P = 0.02), and signifi-
cantly increased total antioxidant capacity (TAC)
(+ 70.1 ± 130.9 vs. − 19.7 ± 124.6 mmol/L, P = 0.009) and
total glutathione (GSH) levels (+ 28.7 ± 61.5 vs.
− 14.9 ± 85.3 μmol/L, P = 0.02). Supplementation with
synbiotic had a significant decrease in cesarean section rate
(16.7 vs. 40.0%, P = 0.04) , lower incidence of
hyperbilirubinemic newborns (3.3 vs. 30.0%, P = 0.006),
and newborns’ hospitalization (3.3 vs. 30.0%, P = 0.006)
compared with the placebo. Synbiotic supplementation did
not affect plasma nitric oxide (NO) levels and other pregnancy
outcomes. Overall, synbiotic supplementation among GDM
women for 6 weeks had beneficial effects on serum hs-CRP,
plasma TAC, GSH, and MDA; cesarean section; incidence of
newborn’s hyperbilirubinemia; and newborns’ hospitalization
but did not affect plasma NO levels and other pregnancy
outcomes.
http://www.irct.ir: www.irct.ir: IRCT201704205623N108
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Introduction
Gestational diabetes (GDM) is defined as hyperglyce-
mia, insulin resistance, and carbohydrate intolerance
with the onset or first recognition during pregnancy
[1]. The prevalence of GDM is 6–20% of pregnant
women, and its prevalence is increasing in parallel with
the obesity epidemic [2, 3]. GDM women have an in-
creased risk of adverse maternal and perinatal complica-
tions, including preeclampsia, hydramnios, increased op-
erative intervention and future type 2 diabetes mellitus,
macrosomia, congenital anomalies, metabolic abnormal-
ities, and subsequent childhood and adolescent obesity
[4]. In addition, increased levels of inflammatory medi-
ators and biomarkers of oxidative stress can induce ma-
ternal insulin resistance, DNA damage, and chromosom-
al aberrations [5, 6].
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Prior studies have documented that throughout pregnancy,
the gut microbiota undergoes significant changes [7, 8]. These
changes in the gut microbiota can result in maternal inflam-
mation, hyperglycemia, and insulin resistance [9]. Recently,
few studies have reported beneficial effects of probiotics and
synbiotics on metabolic profiles among pregnant women and
diseases related to metabolic disorders. We have previously
indicated that probiotic intake among GDM women for
6 weeks had beneficial effects on inflammatory and oxidative
stress parameters but did not influence pregnancy outcomes
[10]. Consumption of probiotic-rich food in pregnant women
was associated with lower rates of preterm birth and pre-
eclampsia [11], which may be attributed to the beneficial ef-
fects of probiotic administration on placental inflammatory
responses [12]. In addition, synbiotic administration for
6 weeks among subjects with GDM improved markers of
insulin metabolism, triglycerides, and VLDL-cholesterol
values [13]. The positive effects of synbiotic administration
for 8 weeks in overweight and obese children on inflammation
markers, which were dependent to its effect on weight reduc-
tion, have also been reported [14].
To our knowledge, data on the effects of synbiotics on
pregnancy outcomes in GDM women are scarce. In addition,
data on the effects of probiotic supplementation on biomarkers
of inflammation and oxidative stress are conflicting.
Therefore, we hypothesized that synbiotic intake might affect
pregnancy outcomes of GDM population. This study was,
therefore, carried out to investigate the effects of synbiotic
supplementation on pregnancy outcomes in GDM women.
Methods
Trial Design and Participants
This randomized, double-blind, placebo-controlled clinical
trial, registered in the Iranian registry of clinical trials (http://
www.irct.ir: IRCT201704205623N108), was performed
among 60 patients with GDM aged 18–40 years old based
on the American Diabetes Association guidelines [15] who
were referred to the Akbarabadi clinic affiliated to Iran
University of Medical Sciences (IUMS), Tehran, Iran,
between April 2016 and December 2016. This research was
carried out in accordance with the Declaration of Helsinki.
Written and informed consent was obtained from all
pregnant women. Patients with clinical characteristics at
enrollment, such as preeclampsia, eclampsia, hypo- and hy-
perthyroidism; smokers; and those with kidney or liver dis-
eases and required commencing insulin therapy during inter-
vention and taking any probiotic and/or synbiotic products
including probiotic yogurt and kefir during the trial were the
exclusion criteria.
Study Design
Participants were randomly allocated into two treatment groups
to intake either one synbiotic capsule containing Lactobacillus
acidophilus strain T16 (IBRC-M10785), L. casei strain T2
(IBRC-M10783) and Bifidobacterium bifidum strain T1
(IBRC-M10771) (2 × 109 CFU/g each) plus 800 mg inulin
(HPX) (n = 30) or placebo (n = 30) for 6 weeks. It is well known
that it would be more appropriate if the strains used for human
consumption originated from the human intestinal tract, well
characterized, able to survive the rigors of the digestive tract
and possibly colonize, biologically active against the target as
well as to be stable and amenable to commercial production
and distribution [16]. We used the above-mentioned doses of
probiotic bacteria based on a previous study in GDM women
[17] and dose of inulin based on a previous study in healthy
pregnant women [18]. Both synbiotic and placebo capsules were
produced by the Tak Gen Zist Pharmaceutical Company in
Tehran, Iran, and approved by the Food and Drug
Administration. To assess the compliance, patients were request-
ed to bring the medication container. To ensure adherence, pa-
tients received a short message on their cell phones to intake the
supplements daily. Randomization assignment was conducted
using computer-generated random numbers. Randomization
and allocation concealment were conducted by the researchers
and patients and were done by a trained staff at the gynecology
clinic. All participants based on standard protocol consumed
400 μg/day of folic acid starting at the beginning of pregnancy
and 60 mg/day ferrous sulfate as of the second trimester. For
assessment of dietary micro- and macro-nutrient intakes, patients
were instructed to record their daily dietary intakes for 3 days,
including oneweekend day and twoweekdays at weeks 1, 3, and
5. Dietary intakes were then analyzed using Nutritionist IV soft-
ware (First Databank, San Bruno, CA) modified for Iranian
foods.
Assessment of Anthropometric Variables
At baseline and end-of-trial, all patients underwent standard an-
thropometric measurements: height and weight (Seca, Hamburg,
Germany). BMI was calculated as weight in kilograms divided
by height in meters squared. Weight and length of all newborns
were measured in labor ward following the birth by a trained
midwife by the use of standard methods (Seca 155 Scale,
Hamburg, Germany). Infants’ head circumference was calculat-
ed to the nearest 1 mmwith a Seca girth measuring tape.We also
determined infants’ 1- and 5-min Apgar scores.
Outcomes
Primary outcomes were inflammatory markers. The second-
ary outcomes were biomarkers of oxidative stress and preg-
nancy outcomes.
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Clinical Assessment
Polyhydramnios was diagnosed using the sonographic estima-
tion method at post-treatment. On the basis of this measure-
ment, polyhydramnios was defined as an amniotic fluid index
(AFI) in excess of 25 cm [19]. Preterm delivery was described
as delivery occurred at <37 weeks of pregnancy, and new-
born’s macrosomia was defined as birth weight of >4000 g.
Assessment of Biochemical Variables
Ten milliliters of fasting blood samples was obtained from
each patient at baseline and the end of the treatment, at the
IUMS reference laboratory. Serum high-sensitivity C-reactive
protein (hs-CRP) levels were determined using ELISA kit
(LDN, Nordhorn, Germany). Spectrophotometric methods
were used to assess nitric oxide (NO) [20], total antioxidant
capacity (TAC) [21], total glutathione (GSH) [22], and
malondialdehyde (MDA) values [23]. The hs-CRP is a gener-
al marker for inflammation, so it can be used as a very rough
proxy for heart disease risk [24]. The TAC considers the oc-
currence of a synergic function of all antioxidants present in
organic fluids, providing an integrative system between such
compounds [25]. Thus, TAC has a higher predictive capacity
and biological relevance when compared to the activity of a
single antioxidant. In addition, MDA is the breakdown prod-
uct of the most important chain reactions leading to the oxi-
dation of polyunsaturated fatty acids and therefore serves as a
reliable oxidant marker of oxidative stress-mediated lipid per-
oxidation [26]. Newborns’ hyperbilirubinemia was consid-
ered when the total serum bilirubin levels were at 15 mg/dL
or more among infants who were 25 to 48 h old, 18 mg/dL in
infants who were 49 to 72 h old, and 20mg/dL in infants older
than 72 h [27].
Sample Size
Using a formula suggested for clinical trials, having 25 pa-
tients in each group was adequate while considering a type
one error (α) of 0.05 and type two error (β) of 0.20 (pow-
er = 80%), 0.44 μg/mL as SD and 0.35 μg/mL as the mean
distinction (d) of hs-CRP as a primary outcome [10].
Assuming 5 dropouts in each group, the final sample size
was determined to be 30 patients in each group.
Statistical Analysis
The Kolmogorov-Smirnov test was used to control the normal
distribution of variables. Independent sample t test was used to
establish changes in anthropometric measures and dietary in-
takes between the two groups. To determine the effects of
synbiotic administration on biochemical variables, we used
one-way repeated measures analysis of variance. To control
some confounding variables including baseline values, mater-
nal age and baseline BMI, we used ANCOVA test using gen-
eral linear models. Differences in proportions were evaluated
by Chi-square test. P < 0.05 was considered statistically sig-
nificant. All statistical analyses were conducted using the
Statistical Package for Social Science version 18 (SPSS Inc.,
Chicago, Illinois, USA).
Results
As revealed in the study flow diagram (Fig. 1), 60 pregnant
women [synbiotic (n = 30) and placebo (n = 28)] completed
the trial. On average, the compliance rate in the current study
was high, such that 90% of synbiotic capsules were consumed
throughout the study in both groups.
Mean age, height, baseline weight, and BMI as well as their
means after the 6-week treatment were not significant between
synbiotic supplements and placebo groups (Table 1).
Considering the 3-day dietary records obtained during the
treatment, there was no significant difference in terms of die-
tary macro- and micro-nutrient intakes between synbiotic and
placebo groups (Data not shown).
After 6 weeks of intervention, compared with the placebo,
synbiotic supplementation significantly decreased serum hs-
CRP (− 1.9 ± 4.2 vs. + 1.1 ± 3.5 mg/L, P = 0.004) and plasma
MDA (− 0.1 ± 0.6 vs. + 0.3 ± 0.7 μmol/L, P = 0.02) and
significantly increased TAC (+ 70.1 ± 130.9 vs.
− 19.7 ± 124.6 mmol/L, P = 0.009) and GSH levels
(+ 28.7 ± 61.5 vs. − 14.9 ± 85.3 μmol/L, P = 0.02)
(Table 2). Supplementation of synbiotic showed no detectable
change in plasma NO levels.
There was a significant difference in baseline levels of
MDA (P = 0.01) between the two groups. Therefore, we ad-
justed the analysis for baseline values of biochemical vari-
ables, maternal age, and BMI at baseline. When we adjusted
the analysis for these variables, findings were not altered
(Table 3).
Supplementation with synbiotic had a significant decrease
in cesarean section rate (16.7 vs. 40.0%, P = 0.04) and lower
incidence of hyperbilirubinemic newborns (3.3 vs. 30.0%,
P = 0.006) and newborns’ hospitalization (3.3 vs. 30.0%,
P = 0.006) compared with the placebo. Synbiotic supplemen-
tation did not affect other pregnancy outcomes (Table 4).
Discussion
This study demonstrated that the 6-week intervention with
synbiotic supplements among women with GDM had benefi-
cial effects on serum hs-CRP, plasma TAC, GSH, and MDA;
cesa r ean sec t i on ; and inc idence o f newborn ’s
hyperbilirubinemia and newborns’ hospitalization, but did
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not affect plasma NO levels and other pregnancy outcomes.
To our knowledge, this is the first to evaluate the effects of
synbiotic supplementation on biomarkers of inflammation and
oxidative stress and pregnancy outcomes in GDM women.
Pregnancy and GDM are associated with several adverse
outcomes for mothers and newborns in the short and long term
[28, 29]. The current study supported that synbiotic supple-
mentation compared with the placebo for 6 weeks among
GDM women resulted in significant decreases in serum hs-
CRP and plasma MDA concentrations and significant eleva-
tions in TAC and GSH levels, but did not affect plasma NO
levels. In line with our results, treatment with synbiotics in
subjects with multiple injuries resulted in a significant reduc-
tion in CRP concentrations in patients who either did or did
not develop sepsis [30]. Jafarnejad et al. [31] exhibited that a
mixture of probiotic (VSL no.3) in women with GDM after
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Analyzed (n=30)
Allocated to intervention (n=30)
Lost to follow-up (n=0)
Analyzed (n=30)
Assessed for eligibility among 
GDM women (n=65)
Excluded (n=5) 
- Not meeting inclusion criteria (n= 5) 
En
ro
llm
en
t
A
llo
ca
tio
n
Fo
llo
w
-u
p
A
na
ly
sis
Screening for GDM among 
pregnant women (n=790)
Excluded (n=725) 
- Had not GDM (n= 718)
- Needed to start insulin therapy (n= 7)
Fig. 1 Summary of patient flow
diagram
Table 1 General characteristics
of the study participantsa Placebo group (n = 30) Synbiotic group (n = 30) P value
b
Maternal age (year) 26.2 ± 3.1 27.2 ± 5.9 0.39
Height (cm) 160.9 ± 3.2 161.8 ± 4.3 0.36
Weight at study baseline (kg) 73.1 ± 5.8 74.7 ± 10.5 0.47
Weight at end-of-trial (kg) 75.2 ± 5.8 77.0 ± 10.4 0.40
Weight change (kg) 2.1 ± 0.9 2.3 ± 0.7 0.23
BMI at study baseline (kg/m2) 28.3 ± 2.5 28.6 ± 4.3 0.72
BMI at end-of-trial (kg/m2) 29.1 ± 2.5 29.5 ± 4.2 0.65
BMI change (kg/m2) 0.8 ± 0.3 0.9 ± 0.3 0.28
a Data are means ± standard deviation
bObtained from independent sample t test
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8 weeks affected the inflammatory cytokines, including hs-
CRP. In addition, in a meta-analysis study conducted by Liu
et al. [32], a significant decrease in CRP levels without any
change in other inflammatory cytokines was observed follow-
ing supplementation with probiotics in subjects with colorec-
tal cancer after operation. Furthermore, we have previously
documented that synbiotic intake for 8 weeks among subjects
with rheumatoid arthritis (RA) had beneficial effects on hs-
CRP and GSH levels, but did not change other inflammatory
and oxidative stress parameters [33]. Moreover, several stud-
ies have documented antioxidant properties of special strains
of lactic acid bacteria [34, 35]. Synbiotic administration for
30 days also had positive effects on TAC and MDA concen-
trations in breastmilk [36]. However, no significant change of
L. casei supplementation for 8 weeks was seen on parameters
of oxidative stress of subjects with RA [37]. Changes in the
gut and vaginal microbiome [38] might influence maternal
biomarkers of inflammation and oxidative stress, which in
turn would result in metabolic and immunological disorders
of the offspring [39]. GDM is associated with increased con-
centrations of oxidative stress, due to overproduction of reac-
tive oxygen species (ROS) and/or defects in antioxidant de-
fenses [40]. Overproduction of ROS induces oxidative dam-
age in membrane lipids, proteins, and DNA, such as purine
and pyrimidyne bases and, as a consequence, single-strand
breaks, double-strand breaks, and DNA-DNA or DNA-
proteins cross-links [41, 42]. In addition, increased oxidative
stress during embryonic, fetal, and placental development
may cause several pregnancy-related disorders, including
embryopathies, spontaneous abortions, preeclampsia, preterm
labor, and low birth weight [43]. Therefore, synbiotic supple-
mentation in GDMwomen may decrease complications relat-
ed to oxidative stress due to its antioxidative effects. However,
increased levels of inflammatory markers were reported in
GDM women [44], the importance of reducing systemic in-
flammation in these patients is still incompletely understood.
The up-regulation of gene expression of interleukin-18 by
produced short-chain fatty acids (SCFA) [45] and increased
production of methylketones family in the colon following
intake of synbiotic [46] might justify its anti-inflammatory
effects. In addition, synbiotic intake may improve oxidative
stress via improved inflammatory factors resulting from pro-
duced SCFA in the gut [47] and its effect in decreased vari-
ables, such as oxidized LDL and 8-isoprostanes [48].
This study documented that synbiotic supplementation
among GDM women decreased cesarean section rate and in-
cidence of newborn’s hyperbilirubinemia and newborns’ hos-
pitalization compared with the placebo, but did not affect
Table 2 Biomarkers of inflammation and oxidative stress at baseline and after the 6-week intervention in women with gestational diabetes that
received either synbiotic supplements or placeboa
Placebo group (n = 30) Synbiotic group (n = 30) P valueb
Wk0 Wk6 Change Wk0 Wk6 Change
hs-CRP (mg/L) 7.3 ± 3.8 8.4 ± 3.9 1.1 ± 3.5 7.8 ± 5.7 5.9 ± 4.3 −1.9 ± 4.2 0.004
NO (μmol/L) 40.7 ± 5.7 39.8 ± 7.1 − 0.8 ± 3.8 41.6 ± 1.8 41.8 ± 2.9 0.2 ± 3.0 0.23
TAC (mmol/L) 930.9 ± 124.3 911.2 ± 100.2 − 19.7 ± 124.6 970.1 ± 86.9 1040.2 ± 129.6 70.1 ± 130.9 0.009
GSH (μmol/L) 470.5 ± 77.9 455.6 ± 96.3 − 14.9 ± 85.3 486.2 ± 71.0 514.9 ± 68.9 28.7 ± 61.5 0.02
MDA (μmol/L) 2.9 ± 0.9 3.2 ± 1.2 0.3 ± 0.7 2.4 ± 0.5 2.3 ± 0.6 − 0.1 ± 0.6 0.02
GSH total glutathione, hs-CRP high-sensitivity C-reactive protein, MDA malondialdehyde, NO nitric oxide, TAC total antioxidant capacity
a All values are means ± SDs
bP values represent the time × group interaction (computed by analysis of the repeated measures ANOVA)
Table 3 Adjusted changes in
biomarkers of oxidative stress and
inflammation in women with
gestational diabetes that received
either synbiotic supplements or
placeboa
Placebo group (n = 30) Synbiotic group (n = 30) P valueb
hs-CRP (mg/L) 1.0 ± 0.6 − 1.8 ± 0.6 0.002
NO (μmol/L) − 0.9 ± 0.6 0.3 ± 0.6 0.20
TAC (mmol/L) − 29.9 ± 19.9 80.3 ± 19.9 < 0.001
GSH (μmol/L) − 17.4 ± 13.0 31.3 ± 13.0 0.01
MDA (μmol/L) 0.3 ± 0.1 − 0.1 ± 0.1 0.02
GSH total glutathione, hs-CRP high-sensitivity C-reactive protein,MDAmalondialdehyde, NO nitric oxide, TAC
total antioxidant capacity
a All values are means ± SE
bObtained from ANCOVA-adjusted based on maternal age, BMI at baseline, and baseline values of biochemical
parameters
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other pregnancy outcomes. In a study by Dugoua et al. [49], it
was seen that Lactobacillus and Bifidobacterium had no de-
tectable effect on the incidence of cesarean section, newborns’
weight, and gestational age. In another study, Demirel et al.
[50] showed that Saccharomyces boulardii supplementation
at a dosage of 250 mg in infants with a gestational age of
≤32 weeks and a birth weight of ≤1500 g decreased their
serum bilirubin levels and the duration of phototherapy.
However, we have previously indicated no significant change
in the incidence of newborns’ hyperbilirubinemia and cesare-
an section rate after supplementation with a synbiotic food
containing L. sporogenes and inulin in healthy pregnant wom-
en [18]. In addition, in a meta-analysis study conducted by
Taylor et al. [51], no significant effects on gestational weight
gain, delivery method or neonatal outcomes, and metabolic
profiles except insulin resistance were documented following
supplementation with probiotic for 6–8 weeks in GDM wom-
en. It has been shown that supplementation with some species
of probiotics could change the intestinal flora, suppress the
activity of β-glucuronidase, and might accelerate the bilirubin
metabolism, which in turn leads to decreasing the
enterohepatic circulation [52]. The aim of controlling the
hyperbilirubinemia is to prevent the indirect bilirubin levels
from reaching the point at which neurotoxicity may occur
[53].
The current study had few limitations. Firstly, we did not
evaluate the effects of synbiotic supplementation on other
pregnancy outcomes, such as the infant respiratory status
and the time in neonatal intensive care unit. Due to funding
limitations, we did not assess the compliance to synbiotic
intake through quantifying fecal bacteria loads and SCFA.
Therefore, this should be taken into account in the interpreta-
tion of our findings. Although the effect of synbiotic supple-
mentation on other inflammatory cytokines and biomarkers of
oxidative stress, including tumor necrosis factor alpha, inter-
leukins, and superoxide dismutase in GDM women is inter-
esting, its performance is suggested in next studies.
Overall, synbiotic supplementation among GDM women
for 6 weeks had beneficial effects on serum hs-CRP, plasma
TAC, GSH, and MDA; cesarean section; and incidence of
newborn’s hyperbilirubinemia and newborns’ hospitalization,
but did not affect plasma NO levels and other pregnancy
outcomes.
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Table 4 The association of
synbiotic supplementation with
pregnancy outcomes
Placebo group (n = 30) Synbiotic group (n = 30) P valuea
Cesarean section (%) 12 (40.0) 5 (16.7) 0.04b
Preterm delivery (%) 1 (3.3) 0 (0) 0.31b
Preeclampsia (%) 4 (13.3) 4 (13.3) >0.999b
Polyhydramnios (%) 2 (6.6) 1 (3.3) 0.55b
Maternal hospitalization (%) 2 (6.7) 1 (3.3) 0.55b
Macrosomia > 4000 g (%) 3 (10.0) 0 (0) 0.07b
Gestational age (weeks) 39.0 ± 1.1 39.4 ± 1.5 0.24
Newborns’ weight (g) 3373.3 ± 412.1 3181.6 ± 459.8 0.09
Newborns’ length (cm) 50.1 ± 1.9 50.0 ± 2.5 0.77
Newborns’ head circumference (cm) 35.4 ± 2.0 35.2 ± 2.1 0.72
1-min Apgar score 8.90 ± 0.30 8.86 ± 0.34 0.69
5-min Apgar score 9.90 ± 0.30 9.86 ± 0.34 0.69
Newborns’ hyperbilirubinemia (%) 9 (30.0) 1 (3.3) 0.006b
Newborns’ hospitalization (%) 9 (30.0) 1 (3.3) 0.006b
Newborns’ hypoglycemia (%) 2 (6.7) 3 (10.0) 0.64b
Values are means ± SDs for continuous measures and are number (%) for dichotomous variables
b Obtained from Pearson Chi-square test
a Obtained from independent t test
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